Through these clinical trials, we will have more data driving us to pragmatic solutions that can be quickly implemented, are low-cost, and will hopefully cure these patients with poor prognoses.
EU Missions started from the idea that complex societal challenges require a coordinated effort across Europe to deliver impact.The 5 EU Missions are focused on climate change, cancer, ocean and water, 100 climate-neutral and smart cities, and healthy soil. This is our chance to work together towards a healthy, green, and digital future.
Improving the lives of more than 3 million people who are affected by cancer by the year 2030 through preventative and curative programs - living longer and better.
Focused on pragmatic clinical trials, it aims to improve the first-line treatment for patients with metastatic kidney cancer by implementing a routine biomarker, leveraging a unique academic network in Europe.
The De-Escalate project will evaluate whether intermittent intensified androgen deprivation treatment (iADT) in metastatic prostate cancer is not inferior to continuous treatment in terms of oncological benefit while minimizing side effects and resource utilization and improving patient quality of life.
Relapse or refractory acute myeloid leukemia (R/R AML) is a high-impact disease, in which no standard of care exists, and where we have an urgent need for new evidence on possible therapies; AML offers a setting in which methodological innovation will combine powerful instruments of clinical trials with personalized medicine through academic efforts.
The study aims to investigate the prognosis, tolerability, and quality of life of vulnerable or frail older breast cancer patients treated with lower initial dose of CDK 4/6-inhibitors plus endocrine therapy compared to the recommended full dose of CDK 4/6-inhibitors.
IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated and more efficacious immunotherapeutic drugs.
LEGATO is an EU-funded phase III randomised pragmatic clinical trial on Recurrent Glioblastoma.
Liveration is an ambitious, pragmatic multicenter clinical trial in 7 different countries and 20 Hospitals to determine whether in liver surgery to resect cancer, additional ablation of tumor margin produced by scalpels that coagulate with radiofrequency can decrease the cancer recurrence rate and improve patient survival.
The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals.
The PRIME-ROSE vision is access to affordable Precision Cancer Medicine (PCM) that prolongs life at the best quality possible for all cancer patients.
Sagittarius is an ongoing clinical trial project that could help to demonstrate the benefits of a new approach to testing and treating patients with high-risk stage II and stage III colon cancer after they have had surgery.
A European multi-disciplinary clinical project meant to improve the management of patients with poor prognostic ovarian cancer after neoadjuvant chemotherapy.
Strexit2 is proposed to amend the ongoing phase III EORTC clinical trial STRASS2 investigating the added value of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma and to add an observational arm Strexit2 that will capture real world data from patients not participating to STRASS2.
« We aim to give hope to our patient »
Doctor Winan Van Houdt
from Legato Project
